
Compare first-line EGFR-mutant NSCLC options, weighing amivantamab–lazertinib vs chemo–osimertinib, plus practical start-up and prevention tips.
Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, and Wade Iams, MD, MSCI, of Tennessee Oncology, work through how they choose among first-line options for EGFR exon 19 deletion and L858R advanced non–small cell lung cancer. Both favor a combination regimen over third-generation tyrosine kinase inhibitor monotherapy, citing the overall survival advantage seen with amivantamab plus lazertinib in MARIPOSA and with platinum-based chemotherapy plus osimertinib in FLAURA2. Dr Santos cites 3-year intracranial progression-free survival of 36% with the combination vs 18% with osimertinib in MARIPOSA as the reason he favors it when brain metastases are present. Dr Iams describes the pragmatic COPERNICUS study, which pairs every-4-week subcutaneous amivantamab with prophylactic anticoagulation and enhanced dermatologic prophylaxis, and reports rash falling from roughly 50% to 60% down to 20% to 30%. Dr Santos details his day 1 order set, and across 2 cases the faculty weigh brain metastases, chronic kidney disease, prior thrombosis, travel distance, and patient preference.

Compare first-line EGFR-mutant NSCLC options, weighing amivantamab–lazertinib vs chemo–osimertinib, plus practical start-up and prevention tips.

Experts compare first-line EGFR-mutated NSCLC regimens, showing why subcutaneous amivantamab+lazertinib and chemo+osimertinib boost survival.

Wade Iams, MD, MSCI, of Tennessee Oncology, describes how he opens the first treatment conversation with patients who have EGFR-mutated advanced non–small cell lung cancer and with their families, after Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, notes that grade 3 or higher adverse events were more common with amivantamab plus lazertinib than with osimertinib in MARIPOSA.

Wade Iams, MD, MSCI, of Tennessee Oncology, presents the first clinical scenario in this OncLive My Treatment Approach discussion with Edgardo Santos, MD, FACP, FASCO, of Starling Oncology: a 58-year-old woman who never smoked, with a 6-week history of progressive cough.

Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, details the orders he places on day 1 for a patient starting subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.

Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, describes how he follows patients through the first months of subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.

Wade Iams, MD, MSCI, of Tennessee Oncology, gives Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, an overview of COPERNICUS, a study of subcutaneous amivantamab plus lazertinib in first-line EGFR-mutated advanced non–small cell lung cancer.

Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, tells Wade Iams, MD, MSCI, of Tennessee Oncology, what he tells patients to expect over the longer term from subcutaneous amivantamab plus lazertinib in EGFR-mutated advanced non–small cell lung cancer, noting that COPERNICUS is still ongoing.

Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, presents the second clinical scenario in this OncLive My Treatment Approach discussion with Wade Iams, MD, MSCI, of Tennessee Oncology: a retired man and former smoker with weight loss, fatigue, and right-sided back pain.

Wade Iams, MD, MSCI, of Tennessee Oncology, works through regimen selection for a retired man with stage IVB lung adenocarcinoma, an EGFR L858R mutation, multiple bone metastases, chronic kidney disease stage 3a, and a remote provoked deep vein thrombosis (DVT).

Wade Iams, MD, MSCI, of Tennessee Oncology, describes managing an acneiform rash of the face and chest that develops at week 3 in a patient receiving subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.

Wade Iams, MD, MSCI, of Tennessee Oncology, explains how his team keeps patients on prophylactic strategies when starting subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer: repeated touches from multiple members of the care team over time, including his own counseling, nursing education at the injection visit, a call from a specialty pharmacist for the oral agent, and follow-up by advanced practice providers.